Visual and anatomical outcomes of anti-vascular endothelial growth factor therapy in exudative age-related macular degeneration and vitreomacular interface disease: Vitreomacular adhesion and epiretinal membrane

摘要

PURPOSE: To describe clinical and imaging features of eyes with and without vitreomacular interface disease (VMID) treated with intravitreal anti-vascular endothelial growth factor injections for exudative age-related macular degeneration, followed over an average of 2.5 years. METHODS: Retrospective interventional case series involving 32 eyes with VMID and 146 eyes without traction. Best-corrected visual acuity (BCVA), manually measured central foveal thickness from optical coherence tomography imaging, and the number and timing of intravitreal anti-vascular endothelial growth factor injections were reviewed. RESULTS: Eyes with VMID and exudative age-related macular degeneration received more intravitreal injections (mean 14.7) for 4 years than eyes without traction (mean 9.5) (P = 0.0224). Eyes with VMID had similar BCVA to eyes without traction at baseline (P = 0.8013) and Year 1 through Year 4 (P = 0.5417, 0.6275, 0.4574, 0.0570, respectively). Best BCVA showed significant improvement over baseline BCVA in eyes with (logarithm of the minimum angle of resolution 0.67-0.47, P = 0.0182) and without (logarithm of the minimum angle of resolution 0.61-0.44, P = 0.0001) VMID. Central foveal thickness was similar to eyes without traction at baseline and Year 1 through Year 3 and declined over time in eyes with VMID. CONCLUSION: In eyes with VMID, anti-vascular endothelial growth factor therapy resulted in improved BCVA and decreased central foveal thickness despite continued vitreomacular traction. Eyes with VMID required more intravitreal anti-vascular endothelial growth factor agents than eyes without VMID.